Timeless Wealth Staff Newsletter
If you are having trouble viewing this message, please go to http://community.icontact.com/p/timelesswealth/newsletters/alert09142009/posts/timelesswealthnet-imuc-to-uplist-to-amex ImmunoCellular Therapeutics (IMUC.ob) has met requirements to list its stock on the NYSE Amex. What does this mean -Better Liquidity -Greater scope of Broker-Dealers Recommending this stock -Entry of Institutional Investors (“funds”) -Higher Stock Price (as a result of increased demand for shares) I strongly believe that the company will announce, in an upcoming statement, intention or application to uplist its common stock. I`ve talked about this company previously – all that`s changed since then is its stock price (which has gone up notably) and financial stability (company successfully raised $8.1M privately).
On the topic of raising $8.1M, the company will be able to produce clinical trial results faster than it had expected in its study of its lead cancer drug (ICT-107). For details see this article. In addition, the company now meets the shareholder`s equity requirement for listing on the AMEX. Market cap is at least $58M (excluding warrants), also meeting the capitalization quota for AMEX listing. Here`s a detailed look at what is required (observe `standard 3`).
To benchmark what you can expect when IMUC uplists, look at another biotech that recently made the jump from OTCBB to AMEX exchange:
Neoprobe Corp. (NEOP) revealed on the 7th of February that it would start trading on the AMEX. To date their stock price soared as much as 53% on increasing volume. Remember the improved liquidity characteristic I talked about (above) As with any investment, there are risks involved when investing in ImmunoCellular Therapeutics (IMUC.ob) stock. But a smart investor is never willing to forgo opportunity and potential reward that far outpaces the implied risks. I think that`s what we have here: reward that greatly outweighs risk.
I`m so confident in my thesis that I`ve put my money where my mouth is and bought shares of this company for a mid to long-term holding.
Best Regards, Edward Stevenson.
Founder, TimelessWealth.net Please note well:
The employees of TimelessWealth.net are not Registered as Investment Advisors in any jurisdiction whatsoever. Full disclaimer can be read here.
TimelessWealth.net `s staff reserve the right to buy shares of the companies discussed in this opinion and may profit in the event those shares rise in value. TimelessWealth.net may liquidate part or all of any such shares without written notice.
References 1. http://seekingalpha.com/article/250575-immunocellular-therapeutics-resemblance-to-dendreon-at-a-fraction-of-the-cost 2. http://timelesswealth.net/disclaimer.html This message was sent to from:
TimelessWealth.net | PO BOX 30559 10660 Yonge Street | Richmond Hill, Ontario L4C 0C7, Canada